What is the Origin of CJC-1295 DAC Half-Life?

The term originates from the field of pharmaceutical development and pharmacokinetics, specifically the strategic engineering of peptide therapeutics to enhance their systemic stability and duration of action. CJC-1295 is a modified GHRH analogue, and the DAC component represents a deliberate molecular strategy to extend its presence in the body. This innovation was driven by the need to improve patient adherence and the overall therapeutic efficacy of injectable peptides.

What is the Mechanism of CJC-1295 DAC Half-Life?

The extended half-life mechanism is based on bioconjugation, where the DAC segment of the peptide forms a covalent bond with circulating albumin, a major plasma protein. This binding shields the peptide from rapid enzymatic degradation and reduces its clearance rate by the kidneys. The bound peptide acts as a slow-release reservoir, continuously dissociating from albumin to engage the pituitary gland, thereby promoting a sustained, physiological pattern of endogenous Growth Hormone (GH) release.

CJC-1295 DAC Half-Life ∞ Area

CJC-1295 DAC Half-Life

Meaning

CJC-1295 DAC Half-Life refers to the significantly extended period required for the concentration of the synthetic peptide CJC-1295 with Drug Affinity Complex (DAC) to decrease by fifty percent in the systemic circulation. This prolonged pharmacokinetic profile is a direct result of the DAC modification, which chemically facilitates binding to endogenous serum albumin. The resulting stable, long-acting nature of the peptide differentiates it from short-acting growth hormone-releasing hormone (GHRH) analogues, allowing for a much less frequent, convenient dosing schedule.